Neurizon Therapeutics

What Neurizon Therapeutics does

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage Australian biotechnology company headquartered in Melbourne that develops NUZ-001 (S-Monepantel), the S-enantiomer of the anthelmintic compound monepantel, repurposed as a small-molecule treatment for amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease. The asset has completed Phase 1 and a 12-month Open Label Extension study in a small Australian ALS cohort, where treatment was safe and generally well tolerated with encouraging exploratory signals across survival, functional decline, and respiratory outcomes, and is now being evaluated as Regimen I of the HEALEY ALS Platform Trial, a multicenter, double-blind, placebo-controlled Phase 2/3 study led by Mass General Brigham in collaboration with NEALS at over 70 US clinical sites.

The business model is pre-revenue and centered on advancing NUZ-001 to regulatory approval. Neurizon licenses monepantel under an exclusive global agreement with Elanco Animal Health (July 2025), paying US$9.75M in upfront and milestone payments for the first approved product, up to US$65M in sales-based milestones, and tiered single-digit royalties on global net sales; a long-term GMP-compliant supply agreement with Elanco (June 2026) underpins manufacturing. Commercial revenue will derive from pharmaceutical sales of NUZ-001 once approved, with the company signaling potential expansion into other neurodegenerative diseases post-ALS. Customer engagement today is limited to clinical trial participants and the HEALEY investigator network, and go-to-market is structured as an enterprise regulatory pathway rather than field sales.

Neurizon's near-term value drivers are entirely clinical and regulatory: a AU$7.1M share placement closed in December 2025 funded trial operations through the Phase 2/3 readout now expected in early Q3 CY2027 after the trial cohort was expanded from 160 to 240 participants. Management includes operators with prior roles at AstraZeneca, GlaxoSmithKline, Shire, Roche, and Arcutis, with Dr Ross Murdoch and Dr Chris Freitag providing direct neurology and rare-disease clinical experience. The single-asset, binary-outcome profile makes Neurizon a high-beta, capital-intensive biotech exposure where future commercial revenue is contingent on a single Phase 2/3 readout.

Name

Neurizon Therapeutics

Legal name

Neurizon Therapeutics Limited

Website

https://neurizon.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

1–10 employees

Short description

Neurizon Therapeutics is a clinical-stage Australian biotech developing NUZ-001 (S-Monepantel), a small molecule for amyotrophic lateral sclerosis (ALS), currently in a Phase 2/3 registrational study within the HEALEY ALS Platform Trial.

Ownership category

akta.pro rank

Product category

Neurology Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

akta.pro secondary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Neurodegenerative disease therapeutics
• ALS clinical development
• Small molecule drug development
• Central nervous system drugs
• Biopharmaceutical pipeline

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue stage biotechnology company. Revenue will be generated from commercial sales of NUZ-001 upon regulatory approval. Currently in clinical development phase.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Neurizon Therapeutics develops and is clinically advancing NUZ-001 (S-Monepantel), an investigational small-molecule drug candidate targeting Amyotrophic Lateral Sclerosis (ALS), the most common form of Motor Neurone Disease. The asset is being evaluated as Regimen I within the HEALEY ALS Platform Trial, a Phase 2/3 registrational study. NUZ-001 has completed Phase 1 and 12-month Open Label Extension studies demonstrating safety, tolerability, and encouraging signals across exploratory clinical measures.

Product overview

Neurizon Therapeutics is a single-product biotech company focused on advancing NUZ-001 (S-Monepantel), its lead drug candidate for neurodegenerative diseases, initially targeting amyotrophic lateral sclerosis (ALS). NUZ-001 is the S-enantiomer of monepantel, an anthelmintic compound being repurposed for neurological applications. The product has completed Phase 1 and Open Label Extension studies and is currently in a Phase 2/3 registrational trial (Regimen I) within the HEALEY ALS Platform Trial led by Mass General Brigham.

Differentiator

Problem solved

Functional benefit

Products and services

• NUZ-001 (S-Monepantel) Investigational small-molecule drug candidate (S-enantiomer of monepantel) being developed for the treatment of Amyotrophic Lateral Sclerosis (ALS), the most common form of Motor Neurone Disease. Currently being evaluated in a Phase 2/3 registrational trial as Regimen I within the HEALEY ALS Platform Trial. Has completed Phase 1 and a 12-month Open Label Extension study demonstrating safety, tolerability, and encouraging signals across exploratory clinical measures including survival, functional decline, and respiratory outcomes.

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Four partnerships are on record, tiered minor and core.

• Justine Conway (Elanco)minorOthers · 26 November 2025Ms Justine Conway, Global Head of Business Development at Elanco Animal Health, appointed as Board Observer to support Neurizon's advancement toward late-stage development and HEALEY ALS Platform Trial entry.
• Elanco Animal HealthcoreOEM/ Whitelabel/ Licensing Partner · 1 July 2025Exclusive global licensing agreement securing rights to monepantel, the active pharmaceutical ingredient in NUZ-001. Long-term supply agreement for scalable GMP-compliant manufacturing. Neurizon pays milestone payments of US$9.75 million for first approved product, US$5.2 million for subsequent products, up to US$65 million in sales-based milestones, and tiered single-digit royalties on global net sales.
• Mass General Brigham - Healey & AMG Center for ALScoreStrategic or Co-development Partner · 1 August 2024Collaboration on HEALEY ALS Platform Trial, a multicenter, double-blind, placebo-controlled, adaptive Phase 2/3 clinical trial. Mass General Brigham leads the platform trial designed to accelerate development of potential new ALS therapies by testing multiple investigational drugs simultaneously.
• Network for Excellence in ALS (NEALS)coreStrategic or Co-development Partner · 1 August 2024Collaborative partnership with NEALS for the HEALEY ALS Platform Trial. NEALS provides network infrastructure and expertise to improve trial startup and enrollment efficiencies across clinical sites.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• QurAlis: QurAlis is an emerging ALS-focused biotech developing precision therapeutics for amyotrophic lateral sclerosis, sharing the same indication focus and clinical-stage profile as Neurizon.
• Alector: Alector develops immuno-neurology drugs for neurodegenerative diseases including ALS and frontotemporal dementia, making it a relevant emerging peer in neurodegenerative drug development.
• MediciNova: MediciNova is developing MN-166 (ibudilast) for ALS and other neurological indications, making it a comparable small-cap clinical-stage peer pursuing ALS therapeutics.
• Denali Therapeutics: Denali Therapeutics is developing brain-penetrant therapies for neurodegeneration, with ALS and other neurodegenerative programs, and operates as a well-funded emerging peer in the same therapeutic space.

Direct peers

• AB Science: AB Science is developing masitinib for ALS and other neurodegenerative conditions, making it a directly comparable late-stage clinical peer in the same indication.
• Ionis Pharmaceuticals: Ionis developed tofersen (partnered with Biogen) and operates an antisense platform targeting neurological disorders including ALS, overlapping directly with Neurizon's neurodegenerative CNS focus.
• Biogen: Biogen markets Qalsody (tofersen) for SOD1 ALS and is investing heavily in neurodegenerative disease drug development, making it a directly comparable ALS-focused commercial-stage peer to Neurizon.
• Cytokinetics: Cytokinetics is developing tirasemtiv and other small-molecule therapies for ALS and is the closest US-listed direct competitor focused exclusively on ALS drug development.
• BrainStorm Cell Therapeutics: BrainStorm is developing NurOwn (autologous MSC-based cell therapy) for ALS and represents another late-stage clinical-stage ALS therapeutic peer.

Broad incumbents

• Mitsubishi Tanabe Pharma: Mitsubishi Tanabe commercializes Radicava/Radicut (edaravone), one of the few approved disease-modifying ALS therapies, positioning it as the broad incumbent benchmark in the ALS market.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCxVJX7W2ZlNQZvNcT-G5Tzg
• Xx.com/neurizon_ltd
• LinkedInlinkedin.com/company/neurizon

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurizon Therapeutics